임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 18-05-28 14:29
논문번호 201
논문제목(영문) Benefit of Vasodilating β-Blockers in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention: Nationwide Multicenter Cohort Study
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 공저자
주저자명 Chung J, Han JK
교신저자명 Kim HS
공동저자명 Chung J, Han JK, Kim YJ, Kim CJ, Ahn Y, Chan Cho M, Chae SC, Chae IH, Chae JK, Seong IW, Yang HM, Park KW, Kang HJ, Koo BK, Jeong MH, Kim HS, investigators for Korea Acute Myocardial Infarction Registry (KAMIR)
게제년월일 2017-10-24
ISSN 2047-9980
Impact Factor 5.117
학술지명 Journal of the American Heart Association
서지사항 0집 / 6권 / 10호,   페이지(e007063. - e007063.)
요약초록문
(Abstract) 입력		 BACKGROUND:
Although current guidelines recommend β-blocker after acute myocardial infarction (MI), the role of β-blocker has not been well investigated in the modern reperfusion era. In particular, the benefit of vasodilating β-blocker over conventional β-blocker is still unexplored.

METHODS AND RESULTS:
Using nation-wide multicenter Korean Acute Myocardial Infarction Registry data, we analyzed clinical outcomes of 7127 patients with acute MI who underwent successful percutaneous coronary intervention with stents and took β-blockers: vasodilating β-blocker (n=3482), and conventional β-blocker (n=3645). In the whole population, incidence of cardiac death at 1 year was significantly lower in the vasodilating β-blocker group (vasodilating β-blockers versus conventional β-blockers, 1.0% versus 1.9%; P=0.003). In 2882 pairs of propensity score-matched population, the incidence of cardiac death was significantly lower in the vasodilating β-blocker group (1.1% versus 1.8%; P=0.028). Although incidences of MI (1.1% versus 1.5%; P=0.277), any revascularization (2.8% versus 3.0%; P=0.791), and hospitalization for heart failure (1.4% versus 1.9%; P=0.210) were not different between the 2 groups, incidences of cardiac death or MI (2.0% versus 3.1%; P=0.010), cardiac death, MI, or hospitalization for heart failure (3.0% versus 4.5%; P=0.003), cardiac death, MI, or any revascularization (3.9% versus 5.3%; P=0.026), and cardiac death, MI, any revascularization, or hospitalization for heart failure (4.8% versus 6.5%; P=0.011) were significantly lower in the vasodilating β-blocker group.

CONCLUSIONS:
Vasodilating β-blocker therapy resulted in better clinical outcomes than conventional β-blocker therapy did in patients with acute MI in the modern reperfusion era. Vasodilating β-blockers could be recommended preferentially to conventional ones for acute MI patients.
파일  C201-Benefit of Vasodilating B-Blockers in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention Nationwide Multicenter Cohort Study..pdf (2.1M) DATE : 2018-05-28 14:29:20